Ascentage Pharma Group International (NASDAQ:AAPG) Raised to “Strong-Buy” at China Intl Cap

Ascentage Pharma Group International (NASDAQ:AAPG) was upgraded by analysts at China Intl Cap to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

AAPG has been the subject of several other reports. Rodman & Renshaw started coverage on shares of Ascentage Pharma Group International in a research note on Tuesday, January 13th. They set a “buy” rating and a $48.00 price objective for the company. Lucid Cap Mkts upgraded shares of Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Finally, BTIG Research restated a “buy” rating and set a $48.00 price objective on shares of Ascentage Pharma Group International in a research note on Thursday, March 26th. Two research analysts have rated the stock with a Strong Buy rating and five have given a Buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $48.00.

Ascentage Pharma Group International Price Performance

AAPG stock opened at $26.90 on Monday. The firm has a 50 day moving average of $24.01 and a 200 day moving average of $29.08. The company has a current ratio of 1.79, a quick ratio of 1.77 and a debt-to-equity ratio of 0.57. Ascentage Pharma Group International has a 52 week low of $17.56 and a 52 week high of $48.45.

Ascentage Pharma Group International (NASDAQ:AAPG) last released its earnings results on Wednesday, March 25th. The company reported ($0.52) EPS for the quarter. The company had revenue of $24.72 million for the quarter.

Hedge Funds Weigh In On Ascentage Pharma Group International

Several institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at approximately $96,000. ABC Arbitrage SA purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at approximately $204,000. Citadel Advisors LLC purchased a new position in shares of Ascentage Pharma Group International during the 3rd quarter valued at approximately $383,000. Hsbc Holdings PLC purchased a new position in shares of Ascentage Pharma Group International during the 2nd quarter valued at approximately $391,000. Finally, UBS Group AG increased its holdings in shares of Ascentage Pharma Group International by 149.4% during the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.